Open Access

High expression of lncRNA HSD11B1‑AS1 indicates favorable prognosis and is associated with immune infiltration in cutaneous melanoma

  • Authors:
    • Kaiyuan Liu
    • Li Zhang
    • Xiuli Li
    • Jingjun Zhao
  • View Affiliations

  • Published online on: December 20, 2021     https://doi.org/10.3892/ol.2021.13172
  • Article Number: 54
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cutaneous melanoma is an aggressive malignant cancer associated with poor prognosis. Identification of reliable biomarkers for predicting prognosis of melanoma contributes to improved clinical outcome and disease management. Long non‑coding RNAs (lncRNAs) serve a crucial regulatory role of oncogenesis and tumor suppression in melanoma. Using data from The Cancer Genome Atlas database, novel lncRNA 11β‑hydroxysteroid dehydrogenase type 1‑antisense RNA 1 (HSD11B1‑AS1) was identified, which was significantly downregulated in malignant melanoma and its downregulation was significantly associated with poor clinicopathological characteristics, including advanced T and pathological stage, Clark level, Breslow depth and ulceration and worse prognosis. Multivariate analysis showed that HSD11B1‑AS1, as well as N stage and Breslow depth, were independent prognostic factors in cutaneous melanoma, and nomograms suggested a good predictive value of 1‑, 3‑ and 5‑year overall survival, progression‑free interval and disease‑specific survival. In vitro experiments verified the decreased HSD11B1‑AS1 expression in melanoma cell lines compared with human epidermal melanocytes. Moreover, cell experiments in vitro, including Cell Counting Kit‑8, colony formation, wound healing and Transwell assay, suggested that overexpression of HSD11B1‑AS1 significantly inhibited melanoma cell proliferation, migration and invasion. Functional enrichment showed significantly enriched pathways in IFN‑γ and ‑α response, TNF‑α signaling via NF‑κB and IL‑2/STAT‑5 and IL‑6/JAK/STAT‑3 signaling. In addition, immune infiltration analysis demonstrated that HSD11B1‑AS1 may function by accelerating immune response regulation and the immune cell infiltration of various immunocytes, especially T, T helper 1, activated dendritic and B cells. The present study revealed HSD11B1‑AS1 as a potential therapeutic target and promising biomarker for diagnosis and prognosis of cutaneous melanoma.
View Figures
View References

Related Articles

Journal Cover

February-2022
Volume 23 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu K, Zhang L, Li X and Zhao J: High expression of lncRNA <em>HSD11B1‑AS1</em> indicates favorable prognosis and is associated with immune infiltration in cutaneous melanoma. Oncol Lett 23: 54, 2022.
APA
Liu, K., Zhang, L., Li, X., & Zhao, J. (2022). High expression of lncRNA <em>HSD11B1‑AS1</em> indicates favorable prognosis and is associated with immune infiltration in cutaneous melanoma. Oncology Letters, 23, 54. https://doi.org/10.3892/ol.2021.13172
MLA
Liu, K., Zhang, L., Li, X., Zhao, J."High expression of lncRNA <em>HSD11B1‑AS1</em> indicates favorable prognosis and is associated with immune infiltration in cutaneous melanoma". Oncology Letters 23.2 (2022): 54.
Chicago
Liu, K., Zhang, L., Li, X., Zhao, J."High expression of lncRNA <em>HSD11B1‑AS1</em> indicates favorable prognosis and is associated with immune infiltration in cutaneous melanoma". Oncology Letters 23, no. 2 (2022): 54. https://doi.org/10.3892/ol.2021.13172